Form 4: Zoetis Executive Vice President Jeannette Ferran Astorga Reports Stock Option and Restricted Stock Unit Grants

Executive Vice President Jeannette Ferran Astorga reports the acquisition of stock options and restricted stock units in Zoetis Inc.

Summary

• Jeannette Ferran Astorga, an Executive Vice President at Zoetis Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the grant of 1,276 restricted stock units (RSUs) on February 19, 2025, which will vest in three equal installments on the first, second, and third anniversaries of the grant date.
• Additionally, Astorga was granted 4,973 stock options on February 19, 2025, also vesting in three equal installments over three years.
• The report also mentions existing RSUs and stock options from previous grants in 2020, 2021, 2022, 2023 and 2024.
• Each RSU represents a contingent right to receive one share of Zoetis Inc. common stock, and each option expires ten years from the grant date.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests continued commitment from the executive.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Executive compensation packages including stock options and RSUs are common in the pharmaceutical industry to attract and retain talent and align executive incentives with shareholder value.

Comparison to Industry Standards

• Zoetis' executive compensation practices, including the use of stock options and RSUs, are generally in line with industry standards for large pharmaceutical companies.
• Companies like Eli Lilly, Merck, and Pfizer also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedules and grant sizes are likely determined based on factors such as company performance, individual contribution, and market benchmarks.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive interests with company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership team.
• The grants have no immediate impact on customers, suppliers, or creditors.

Key Dates

Keywords

Zoetis, Form 4, Executive Compensation, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading